Surgery, Needle Fasciotomy, or Collagenase Injection for Dupuytren Contracture : A Randomized Controlled Trial
- PMID: 38346307
- DOI: 10.7326/M23-1485
Surgery, Needle Fasciotomy, or Collagenase Injection for Dupuytren Contracture : A Randomized Controlled Trial
Abstract
Background: Surgery, needle fasciotomy, and collagenase injection are used to treat Dupuytren contracture. The treatment decision requires balancing initial morbidity and costs of surgery against its potential long-term benefits over needle fasciotomy and collagenase.
Objective: To compare the effectiveness of surgery, needle fasciotomy, and collagenase injection at 3 months and 2 years (secondary time points of the trial).
Design: A multicenter, randomized, outcome assessor-blinded, superiority trial. (ClinicalTrials.gov: NCT03192020).
Setting: 6 public hospitals in Finland.
Participants: 302 persons with treatment-naive Dupuytren contracture (contracture angle <135°).
Intervention: Surgery (n = 101), needle fasciotomy (n = 101), or collagenase (n = 100).
Measurements: The primary outcome was the success rate, defined as greater than 50% contracture release and patients reaching the patient acceptable symptom state. Secondary outcomes included hand function, pain, quality of life, patient satisfaction, residual contracture angle, finger flexion, risk for retreatment, and serious adverse events.
Results: A total of 292 (97%) and 284 (94%) participants completed the 3-month and 2-year follow-ups. Success rates were similar at 3 months: 71% (95% CI, 62% to 80%) for surgery, 73% (CI, 64% to 82%) for needle fasciotomy, and 73% (CI, 64% to 82%) for collagenase. At 2 years, surgery had superior success rates compared with both needle fasciotomy (78% vs. 50%; adjusted risk difference [aRD], 0.30 [CI, 0.17 to 0.43]) and collagenase (78% vs. 65%; aRD, 0.13 [CI, 0.01 to 0.26]). Secondary analyses paralleled with the primary analysis.
Limitation: Participants were not blinded.
Conclusion: Initial outcomes are similar between the treatments, but at 2 years success rates were maintained in the surgery group but were lower with both needle fasciotomy and collagenase despite retreatments.
Primary funding source: Research Council of Finland.
Conflict of interest statement
Similar articles
-
DupuytrEn Treatment EffeCtiveness Trial (DETECT): a protocol for prospective, randomised, controlled, outcome assessor-blinded, three-armed parallel 1:1:1, multicentre trial comparing the effectiveness and cost of collagenase clostridium histolyticum, percutaneous needle fasciotomy and limited fasciectomy as short-term and long-term treatment strategies in Dupuytren's contracture.BMJ Open. 2018 Mar 28;8(3):e019054. doi: 10.1136/bmjopen-2017-019054. BMJ Open. 2018. PMID: 29599391 Free PMC article. Clinical Trial.
-
Collagenase Treatment Versus Needle Fasciotomy for Single-Digit Dupuytren Contractures: A Meta-Analysis of Randomized Controlled Trials.J Hand Surg Am. 2023 Dec;48(12):1200-1209. doi: 10.1016/j.jhsa.2023.08.008. Epub 2023 Sep 16. J Hand Surg Am. 2023. PMID: 37725027
-
Injectable Collagenase Versus Percutaneous Needle Fasciotomy for Dupuytren Contracture in Proximal Interphalangeal Joints: A Randomized Controlled Trial.J Hand Surg Am. 2017 May;42(5):321-328.e3. doi: 10.1016/j.jhsa.2017.03.003. J Hand Surg Am. 2017. PMID: 28473158 Clinical Trial.
-
Collagenase clostridium histolyticum for the treatment of Dupuytren's contracture: systematic review and economic evaluation.Health Technol Assess. 2015 Oct;19(90):1-202. doi: 10.3310/hta19900. Health Technol Assess. 2015. PMID: 26524616 Free PMC article. Review.
-
Collagenase injections for treatment of Dupuytren disease.Hand Clin. 2014 Feb;30(1):25-32. doi: 10.1016/j.hcl.2013.08.016. Epub 2013 Oct 25. Hand Clin. 2014. PMID: 24286739 Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources